Drug Profile
Research programme: infectious disease vaccines - Codagenix
Alternative Names: CDX EC; CDX H7N9; CDX-DENV-14; CDX-RSV; CDX-ZiKV; CDX-ZKVLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Codagenix
- Class Dengue vaccines; Escherichia coli vaccines; Influenza A virus H7N9 vaccines; Respiratory syncytial virus vaccines; Vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dengue; Respiratory syncytial virus infections; Zika virus infection
- No development reported Influenza A virus H7N9 subtype
- Discontinued Escherichia coli infections
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Influenza-A virus H7N9 subtype(Prevention) in USA
- 31 Dec 2021 Discontinued - Preclinical for Escherichia coli infections (Prevention) in USA (Parenteral) (Codagenix pipeline, December 2021)
- 08 Feb 2021 Preclinical trials in Dengue (Prevention) is ongoing in USA (Parenteral) (Codagenix pipeline, February 2021)